Brief: Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) For Lupkynis® (Voclosporin) In Japan
13/11/2023 11:06
Nov 13 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O :
* AURINIA PHARMACEUTICALS ANNOUNCES COLLABORATION PARTNER
OTSUKA
FILED NEW DRUG APPLICATION (NDA) FOR LUPKYNIS® (VOCLOSPORIN) IN
JAPAN
* AURINIA PHARMACEUTICALS ANNOUNCES COLLABORATION PARTNER
OTSUKA
FILED NEW DRUG APPLICATION (NDA) FOR LUPKYNIS® (VOCLOSPORIN) IN
JAPAN
Source text for Eikon: ID:nBw42lFSa
Further company coverage: AUPH.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death